DL-AP5 (sodium)

DL-AP5 (2-APV) sodium is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 sodium shows significantly antinociceptive activity. DL-AP5 sodium specifically blocks on channels in the rabbit retina[1][2][3].

Product Specifications

CAS Number

[1303993-72-7]

Product Name Alternative

2-APV (sodium) ; DL-2-Amino-5-phosphonovaleric acid (sodium)

UNSPSC

12352211

Target

IGluR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/dl-ap5-sodium.html

Purity

99.20

Solubility

10 mM in DMSO

Smiles

NC(CCCP(O)(O)=O)C(O[Na])=O

Molecular Formula

C5H11NNaO5P

Molecular Weight

219.11

References & Citations

[1]Murray CW, et al. Neurokinin and NMDA antagonists (but not a kainic acid antagonist) are antinociceptive in the mouse formalin model. Pain. 1991;44 (2) :179-185.|[2]Massey SC, et al. N-methyl-D-aspartate receptors of ganglion cells in rabbit retina. J Neurophysiol. 1990;63 (1) :16-30.|[3]Jafari-Sabet M. NMDA receptor blockers prevents the facilitatory effects of post-training intra-dorsal hippocampal NMDA and physostigmine on memory retention of passive avoidance learning in rats. Behav Brain Res. 2006 Apr 25;169 (1) :120-7.|[4]Taati M, et al. The effects of DL-AP5 and glutamate on ghrelin-induced feeding behavior in 3-h food-deprived broiler cockerels. J Physiol Biochem. 2011 Jun;67 (2) :217-23.|[5]Chen T, et al. Glutamate-induced rapid induction of Arc/Arg3.1 requires NMDA receptor-mediated phosphorylation of ERK and CREB. Neurosci Lett. 2017 Nov 20;661:23-28.